Lantern Pharma launches a cutting-edge AI algorithm

As the pandemic has continued to impact the world, there has been a growing focus on the importance of developing new treatments for a range of diseases, including those affecting the brain. Lantern Pharma, a clinical-stage biopharmaceutical company, has developed cutting-edge AI algorithms that can predict the blood-brain-barrier permeability of any compound. The development of these algorithms has been influenced by the Covid-19 pandemic, which has highlighted the urgent need for innovative medical solutions.

According to GlobalData estimates, the total AI market will be worth $383.3bn in 2030, implying a 21% compound annual growth rate between 2022 and 2030. This breakthrough technology has the potential to revolutionise drug development and improve treatment options for a range of neurological and psychiatric disorders. Lantern Pharma’s AI algorithms have the potential to significantly impact the medical industry by improving the efficiency and effectiveness of drug development. By predicting the blood-brain-barrier permeability of compounds, these algorithms can help drug developers to target their efforts more effectively and develop treatments that are more likely to be successful.

Lantern Pharma’s development of AI algorithms to predict the blood-brain-barrier permeability of compounds has the potential to revolutionise drug development and improve treatment options for a range of neurological and psychiatric disorders. As the medical industry continues to face unprecedented challenges, it is vital that innovative solutions such as these algorithms are developed to ensure that patients receive the best possible care.